CYP2D6 Metabolism of Qelbree (Viloxazine) is Clinically Insignificant
The metabolism of Qelbree through CYP2D6 is minimal and clinically unimportant—CYP2D6 poor metabolizers show only 21-26% higher drug exposure compared to extensive metabolizers, which does not require dose adjustment. 1
Primary Metabolic Pathways
Viloxazine is primarily metabolized by CYP2D6, UGT1A9, and UGT2B15, with the major metabolite being 5-hydroxy-viloxazine glucuronide 1. However, the contribution of CYP2D6 to overall metabolism is limited:
- In humans, 5-hydroxylation (via CYP2D6) followed by glucuronidation is the major route, but this represents only a portion of total metabolism 2
- The fraction metabolized via CYP2D6 suggests a PM/EM difference of less than 2-fold, making clinical significance "highly unlikely" 2
Clinical Evidence of Minimal Impact
CYP2D6 Genetic Polymorphism Study
A dedicated multiple-dose study with 900 mg viloxazine ER demonstrated:
- Cmax was only 21% higher in CYP2D6 poor metabolizers vs. extensive metabolizers
- AUC was only 26% higher in poor metabolizers vs. extensive metabolizers 1
These modest increases (21-26%) fall well below the threshold typically requiring dose adjustment for most medications.
Drug Interaction Study with Strong CYP2D6 Inhibitor
When viloxazine was co-administered with paroxetine (a potent CYP2D6 inhibitor that essentially mimics the poor metabolizer phenotype):
- Cmax increased by only 16% (116% ratio)
- AUC increased by only 35% (135% ratio) 3
This confirms that even complete CYP2D6 inhibition produces minimal clinical impact. All adverse events remained mild in severity 3.
Recent Comprehensive Assessment
A 2024 study specifically evaluating CYP2D6 polymorphisms found:
- Cmax ratio (PM/EM): 121% (90% CI: 102-142%)
- AUC ratio (PM/EM): 126% (90% CI: 105-150%)
- Conclusion: CYP2D6 polymorphisms "did not meaningfully alter the viloxazine ER pharmacokinetic profile" 4
Practical Clinical Implications
No dose adjustment is needed based on CYP2D6 metabolizer status. The FDA label does not recommend:
- CYP2D6 genotyping before initiating therapy
- Dose modifications for known poor metabolizers
- Avoiding co-administration with CYP2D6 inhibitors 1
Key Contrast with Other Medications
This stands in stark contrast to drugs like fluoxetine and paroxetine, which are "initially metabolized through CYP2D6" and where poor metabolizers face "higher risk of toxicity due to elevated blood levels" 5. For those SSRIs, CYP2D6 status can be clinically significant.
Important Caveat
While CYP2D6 metabolism is insignificant for viloxazine, note that viloxazine itself is a weak CYP2D6 inhibitor 4. This means viloxazine can affect the metabolism of other CYP2D6 substrates, though this is a separate consideration from viloxazine's own metabolism.
Bottom line: CYP2D6 metabolizer status does not clinically impact viloxazine exposure or require any prescribing modifications.